Merino Ugarte C
Servicio de Gastroenterologia, Hospital Nacional G. Almenara I.
Rev Gastroenterol Peru. 1995;15 Suppl 1:S101-4.
Identification of so called endothelium derived relaxing factor, EDRF, as nitric oxide, ON, produced in situ in digestive tract, as well as in many other organs, offers the possibility of pharmacologic control blocking or stimulating its production in situ. Theoretically, conditions like achalasia, cell injury by endotoxins, altered visceral arterial flow, hyperdynamic circulatory state in decompensated cirrhosis, protein synthesis and glomerular filtration in ascites, will be amenable of better treatment. This gas is considered as labile humoral-like messenger, mediator or a regulator of cell function in a number of physiological are promising. By now most of the information available comes from animal studies.
所谓的内皮源性舒张因子（EDRF）被鉴定为一氧化氮（NO），它在消化道以及许多其他器官中就地产生，这为通过药理学手段控制其就地产生（阻断或刺激）提供了可能性。从理论上讲，诸如贲门失弛缓症、内毒素引起的细胞损伤、内脏动脉血流改变、失代偿期肝硬化的高动力循环状态、腹水时的蛋白质合成和肾小球滤过等情况，将更易于得到治疗。这种气体被认为是一种不稳定的类体液信使、介质或细胞功能的调节剂，在许多生理过程中都很有前景。目前，大多数可用信息都来自动物研究。
